RLAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RLAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Relay Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -45.58%.
The historical data trend for Relay Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROCE % | Get a 7-Day Free Trial | -20.94 | -9.56 | -25.65 | -30.78 | -41.02 |
Relay Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -40.81 | -46.60 | -34.25 | -45.16 | -45.58 |
Relay Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -379.422 | / | ( ( (1099.771 - 63.709) | + | (843.98 - 30.269) ) | / 2 ) | |
= | -379.422 | / | ( (1036.062 | + | 813.711) | / 2 ) | |
= | -379.422 | / | 924.8865 | ||||
= | -41.02 % |
Relay Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -368.78 | / | ( ( (843.98 - 30.269) | + | (841.441 - 37.144) ) | / 2 ) | |
= | -368.78 | / | ( ( 813.711 | + | 804.297 ) | / 2 ) | |
= | -368.78 | / | 809.004 | ||||
= | -45.58 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relay Therapeutics (NAS:RLAY) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Relay Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Rahmer | officer: See remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Thomas Catinazzo | officer: Vice President, Finance | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Donald A Bergstrom | officer: See Remarks | 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Brian Adams | officer: General Counsel | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Sanjiv Patel | director, officer: President and CEO | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Andy Porter | officer: See Remarks | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Mark Murcko | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Sekar Kathiresan | director | 500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Third Rock Ventures Iii, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Jami Rubin | director | C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139 |
Douglas S Ingram | director | 2525 DUPONT DR, IRVINE CA 92612 |
Third Rock Ventures Gp Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Svf Pauling (cayman) Ltd | 10 percent owner | 27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008 |
Picularium, Llc | 10 percent owner | 1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036 |
Laura Shawver | director | 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
From GuruFocus
By Value_Insider Value_Insider • 10-27-2022
By Marketwired • 11-02-2023
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 04-19-2023
By PurpleRose PurpleRose • 08-04-2022
By Marketwired • 08-01-2023
By sperokesalga sperokesalga • 02-23-2023
By GuruFocus Research GuruFocus Editor • 10-14-2022
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 08-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.